Actively Recruiting
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Led by Kyowa Kirin, Inc. · Updated on 2024-07-24
150
Participants Needed
1
Research Sites
542 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
CONDITIONS
Official Title
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Adults 18 years of age or older with either cutaneous T cell lymphoma (CTCL) or adult T-cell leukemia/lymphoma (ATLL)
- Allogeneic hematopoietic stem cell transplantation performed from January 2012 onward
You will not qualify if you...
- Patients without consent for research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CIBMTR
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
L
Linda J Burns, MD
CONTACT
J
Jatin Jadwani, BDS, MSc Clinical Research
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here